WO2016068547A1 - Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy - Google Patents

Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy Download PDF

Info

Publication number
WO2016068547A1
WO2016068547A1 PCT/KR2015/011246 KR2015011246W WO2016068547A1 WO 2016068547 A1 WO2016068547 A1 WO 2016068547A1 KR 2015011246 W KR2015011246 W KR 2015011246W WO 2016068547 A1 WO2016068547 A1 WO 2016068547A1
Authority
WO
WIPO (PCT)
Prior art keywords
seed oil
ginseng seed
ginseng
composition
present
Prior art date
Application number
PCT/KR2015/011246
Other languages
French (fr)
Korean (ko)
Inventor
김수환
박찬웅
김선미
김완기
이상준
Original Assignee
주식회사 아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아모레퍼시픽 filed Critical 주식회사 아모레퍼시픽
Priority to JP2017523344A priority Critical patent/JP6615200B2/en
Priority to CN201580059489.2A priority patent/CN106999524B/en
Publication of WO2016068547A1 publication Critical patent/WO2016068547A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2124—Ginseng

Definitions

  • the present invention relates to a composition containing ginseng seed oil effective for the prevention and treatment of male prostate hypertrophy.
  • Ginseng (Panax ginseng CA Meyer) is a plant belonging to the genus Ogapiaceae ginseng, which has been used for more than 2,000 years in Korea, China, Japan, etc., and has been used to prevent disease and prolong life.
  • the effects and effects of ginseng on the central nervous system, anti-carcinogenic, anti-cancer, immune-modulatory, anti-diabetic, hepatic anti-inflammatory effect, cardiovascular disorders, anti-arteriosclerosis, blood pressure control, menopausal disorders , Effects on osteoporosis, antistress action, anti-fatigue, antioxidant activity, anti-aging effects are known (latest ginseng "components and potency", Korea Ginseng and Tobacco Research Institute, 56-112, 1996).
  • ginseng seeds contain about 15 ⁇ 26% of oil (Beveridge et al. 2002; Matsumoto et al. 1986), and have a high fatty acid composition similar to olive oil due to high content of monounsaturated fatty acid oleic acid (C18: 1) as a major fatty acid component. It was found to have.
  • ginseng seed oil has been found to have various phytosterols, such as squalene, oxidose squalene, camphorsterol, stigmasterol, cytosterol, etc., which are effective in reducing blood cholesterol.
  • studies on ginseng seeds made up to now include studies on the composition of ginsenosides of ginseng seeds and ginseng roots (Hu et al. 2008), studies on saponin composition of ginseng seeds and pulp, and composition of ginseng seed oil by region.
  • Studies on the composition of ginsenosides and the composition of ginseng seed oil have been reported, including comparative studies on oxidative stability and homeostatic effects of ginseng seeds by autoclaving.
  • the present inventors have studied the new use of ginseng seed oil for human health, and found that ginseng seed oil effectively works to alleviate male prostate hypertrophy, thereby completing the present invention.
  • an object of the present invention is to provide a composition containing ginseng seed oil effective for preventing and treating male prostate hypertrophy.
  • the present invention provides a composition for preventing and treating enlarged male prostate gland containing ginseng seed oil as an active ingredient.
  • composition of the present invention is effective in alleviating and preventing the symptoms of enlarged prostate gland in men, as well as helping to improve human health, such as fatigue recovery, weight loss, cholesterol and triglyceride improvement, and thus, in the food and pharmaceutical fields Can be utilized.
  • 1 is a diagram showing a step of processing ginseng seed oil.
  • the present invention relates to a composition containing ginseng seed oil, which can effectively act in the prevention and treatment of symptoms of enlarged prostate gland in men.
  • the ginseng seed oil used in the present invention is not particularly limited in its processing method, but may be manufactured according to the processing steps shown in FIG. 1, for example. Specifically, the following process is included.
  • the ginseng seed in step (a) includes both sprouted and non- sprouted, raw ginseng seeds, or may be dried through daylight drying or hot air drying.
  • the method of milking ginseng seed in the present invention is not particularly limited, and various known methods may be used.
  • the ginseng seed oil of the present invention can be obtained by a compression method for compressing ginseng seed, which is put into the milking machine in the milking machine and compressed to extract useful components.
  • the milking time is preferably 3 to 20 minutes, milking is usually carried out at room temperature.
  • ginseng seed oil may be extracted by Supercritical Water Extraction.
  • Supercritical extraction is to use a supercritical fluid in a state beyond the critical point, but the type of supercritical fluid to be used is not particularly limited, pentane, carbon dioxide and the like can be used, in particular carbon dioxide may be used.
  • the kind of solvent to be used is not specifically limited, Alcohol or purified water can be used especially as a solvent in this invention.
  • ginseng seed oil may be extracted by subcritical water extraction.
  • Subcritical extraction is used as an extraction solvent when the solvent does not exceed the critical point, and depending on what solvent is selected, it can have the same performance as supercritical extraction, and the type of solvent used is not particularly limited.
  • alcohol or purified water may be used as the solvent.
  • ginseng seed oil may be extracted by microwave extraction.
  • the microwave extraction method is a method that can extract the desired components in a short time while reducing the solvent and saving energy as much as possible, the type of the solvent used is not particularly limited, in particular in the present invention can be used as a solvent or purified water .
  • ginseng seed oil may be extracted by ultrasonic extraction.
  • Ultrasonic extraction is a method of extracting useful components efficiently within a short time without denaturation or loss of the extract, although the type of solvent to be used is not particularly limited, in particular in the present invention, alcohol or purified water can be used as the solvent.
  • composition of the present invention may contain ginseng seed oil in an amount of 0.01 to 100% by weight based on the total weight of the composition, depending on the form of the composition.
  • the preparations of the present invention may also be formulated as pharmaceutical or food compositions in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.
  • the present invention provides a pharmaceutical composition containing the extract of ginseng seed oil according to a conventional method.
  • a carrier in the form of a container.
  • the carrier may be a solid, semisolid or liquid substance which acts as a carrier, excipient or medium for the active ingredient.
  • the formulation may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectables, sterile powders and the like.
  • Suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the formulation may further comprise fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like.
  • Compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
  • composition of the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous, abdominal, muscle, topical application, patch and iontophoresis, of which topical application and oral administration are preferred. Do.
  • a typical daily dosage of the active compound may range from 1 to 100 mg / kg body weight, preferably 5 to 70 mg / kg body weight, and may be administered once or in several doses.
  • the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore the dosage may be determined in any way. Nor does it limit the scope of the present invention.
  • the present invention also provides a food composition containing the ginseng fruit extract according to a conventional method.
  • the food composition of the present invention has a formulation in a liquid or solid state, and the formulation is not particularly limited, and may be, for example, formulated into tablets, granules, drinks, caramels, diet bars, and the like.
  • the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
  • Raw ginseng fruit was harvested and seeds were separated to obtain ginseng seed.
  • Ginseng seed oil was obtained from the ginseng seed obtained as above by using a food milking machine (DS-1500, Dasan Food Industry Machinery, Korea) at room temperature for 5 minutes (yield 0.5 ⁇ 2%).
  • the ginseng seed oil thus obtained was used in the following test example.
  • ginseng seed oil according to the present invention was detected fatty acids and lipids.
  • the urine stem is thin and uncomfortable.
  • the first questionnaire was made for 60 males over 40 with discomfort in urine.
  • the 60 patients were divided into three groups of 20 people.
  • the ginseng seed oil of Example 1 was contained in a dropper container capable of fractionation of 1 ml and contained in 28 milk. That is, the standardized ginseng seed oil was ingested 28ml once a day (ginseng seed oil intake group).
  • the other group was given loric acid for comparison. Specifically, 2.5 mg of loric acid was dissolved in 1 ml of soybean oil, so that 28 ml of soybean oil in which lauric acid was dissolved (ie, 70 mg of total loric acid and the same amount of lauric acid in 28 ml of ginseng seed oil) was consumed.
  • the score of the diagnostic questionnaire was lower for the subjects who consumed ginseng seed oil, and the ingestion of luteic acid, which is known to be good for prostate health by relieving the enlargement of the prostate gland by prostate smooth muscle relaxation, was taken. Compared with, it can be seen that the degree of improvement is remarkably large. Therefore, it can be seen that the intake of ginseng seed oil improves the symptoms of enlarged prostate.
  • the ginseng seed oil of Example 1 was concentrated so that the content of solid content was 20% or more, and matured at low temperature to prepare 100% extract product in liquid form.
  • ginseng seed oil 110 mg of ginseng seed oil, 0.8 mg of palm oil, 0.48 mg of vegetable hardened oil, 2.4 mg of lead, 2.4 mg of lecithin and 3.6 mg of lecithin were mixed and filled according to a conventional method to prepare a soft capsule.
  • ginseng seed oil 160 mg of ginseng seed oil, 200 mg of glucose, and 196 mg of dextrin were mixed and granulated using a fluidized bed dryer, and then, 7 mg of sugar ester was added thereto, and tableted with a tablet press to prepare a tablet.
  • ginseng seed oil of Example 1 0.3 g of sugar, 1.91 g of starch, and 0.56 g of glycerin were mixed, and a ring was prepared using a dehydrator.
  • ginseng seed oil 160 mg of ginseng seed oil, 200 mg of glucose, and 196 mg of dextrin were mixed and granulated using a fluidized bed dryer, followed by filling into a fabric to prepare granules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a composition containing ginseng seed oil which is effective in preventing and treating male prostatic hypertrophy.

Description

인삼씨유를 함유하여 전립선 비대증을 예방 및 치료하는 조성물Contains ginseng seed oil to prevent and treat prostatic hyperplasia
본 발명은 인삼씨유를 함유하여 남성 전립선 비대증의 예방 및 치료에 효과적인 조성물에 관한 것이다.The present invention relates to a composition containing ginseng seed oil effective for the prevention and treatment of male prostate hypertrophy.
인삼(Panax ginseng C.A. Meyer)은 오가피과 인삼속에 속하는 식물로 한국, 중국, 일본 등지에서 2,000여 년 전부터 사용되어 온 생약으로, 경험적으로 질병을 예방하고 수명을 연장시킬 목적으로 사용되어 왔으며, 지금까지 알려진 인삼의 효능 및 효과는 중추신경계에 대한 작용, 항발암 작용, 항암활성 작용, 면역기능 조절 작용, 항당뇨 작용, 간기능 항진효능, 심혈관 장해개선, 항동맥경화 작용, 혈압조절 작용, 갱년기 장애 개선, 골다공증에 미치는 효과, 항스트레스 작용, 항피로 작용, 항산화 활성, 노화억제 효능 등이 알려져 있다(최신고려인삼 "성분 및 효능편", 한국인삼연초연구원, 56-112, 1996).Ginseng (Panax ginseng CA Meyer) is a plant belonging to the genus Ogapiaceae ginseng, which has been used for more than 2,000 years in Korea, China, Japan, etc., and has been used to prevent disease and prolong life. The effects and effects of ginseng on the central nervous system, anti-carcinogenic, anti-cancer, immune-modulatory, anti-diabetic, hepatic anti-inflammatory effect, cardiovascular disorders, anti-arteriosclerosis, blood pressure control, menopausal disorders , Effects on osteoporosis, antistress action, anti-fatigue, antioxidant activity, anti-aging effects are known (latest ginseng "components and potency", Korea Ginseng and Tobacco Research Institute, 56-112, 1996).
한편, 인삼씨는 약 15~26%의 오일을 함유하고 있으며(Beveridge 등 2002; Matsumoto 등 1986), 주요 지방산 성분으로 단일불포화지방산인 올레산(C18:1)의 함량이 높아 올리브 오일과 비슷한 지방산 조성을 갖는 것으로 나타났다.On the other hand, ginseng seeds contain about 15 ~ 26% of oil (Beveridge et al. 2002; Matsumoto et al. 1986), and have a high fatty acid composition similar to olive oil due to high content of monounsaturated fatty acid oleic acid (C18: 1) as a major fatty acid component. It was found to have.
또한 인삼씨 오일에 혈중 콜레스테롤을 감소시키는 효능이 있는 스쿠알렌, 옥시도스쿠알렌, 캄페스테롤, 스티그마스테롤, 시토스테롤 등과 같은 다양한 피토스테롤이 존재하는 것으로 밝혀져 기능성원료로 인삼씨유의 이용가능성이 대두되고 있다. 이 외에 현재까지 이루어진 인삼씨에 관한 연구로는 인삼씨와 인삼근의 진세노사이드 조성에 관한 연구(Hu 등 2008), 인삼씨와 과육의 사포닌 조성에 관한 연구, 산지별 인삼씨 오일의 조성과 산화안정성 비교 연구, 고압살균처리에 따른 인삼씨의 항상화 효과 등 주로 인삼씨의 진세노사이드 조성과 인삼씨 오일의 조성에 관한 연구가 보고되고 있다. 이처럼 인삼씨유의 식품학적 가치는 지속적으로 연구되고 있지만, 인삼 뿌리 및 열매에 대한 연구에 비하여 그 성과는 미미한 것이 현실이다.In addition, ginseng seed oil has been found to have various phytosterols, such as squalene, oxidose squalene, camphorsterol, stigmasterol, cytosterol, etc., which are effective in reducing blood cholesterol. In addition, studies on ginseng seeds made up to now include studies on the composition of ginsenosides of ginseng seeds and ginseng roots (Hu et al. 2008), studies on saponin composition of ginseng seeds and pulp, and composition of ginseng seed oil by region. Studies on the composition of ginsenosides and the composition of ginseng seed oil have been reported, including comparative studies on oxidative stability and homeostatic effects of ginseng seeds by autoclaving. Although the food value of ginseng seed oil is continuously studied, the results are insignificant compared to the research on ginseng root and fruit.
이에 본 발명자들은 인삼씨유의 인체 건강에 대한 신규 용도에 대하여 연구한 결과, 인삼씨유가 남성 전립선 비대증의 완화에 효과적으로 작용함을 발견하여 본 발명을 완성하게 되었다.Accordingly, the present inventors have studied the new use of ginseng seed oil for human health, and found that ginseng seed oil effectively works to alleviate male prostate hypertrophy, thereby completing the present invention.
따라서, 본 발명은 인삼씨유를 함유하여 남성 전립선 비대증 예방 및 치료에 효과적인 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a composition containing ginseng seed oil effective for preventing and treating male prostate hypertrophy.
상기한 목적을 달성하기 위하여, 본 발명은 인삼씨유를 유효성분으로 함유하는 남성 전립선 비대증 예방 및 치료용 조성물을 제공한다.In order to achieve the above object, the present invention provides a composition for preventing and treating enlarged male prostate gland containing ginseng seed oil as an active ingredient.
본 발명의 조성물은 남성의 전립선 비대증 증상을 완화시키고 이를 예방하는데 효과적이며, 이 뿐만 아니라 피로회복, 체중감소, 콜레스테롤 및 중성지방 개선 등의 인체 건강 증진에 도움을 주고, 따라서 식품 및 의약 분야에서 다양하게 활용될 수 있다.The composition of the present invention is effective in alleviating and preventing the symptoms of enlarged prostate gland in men, as well as helping to improve human health, such as fatigue recovery, weight loss, cholesterol and triglyceride improvement, and thus, in the food and pharmaceutical fields Can be utilized.
도 1은 인삼씨유를 가공하는 단계를 나타내는 다이어그램이다.1 is a diagram showing a step of processing ginseng seed oil.
본 발명은 인삼씨유를 함유하여, 남성의 전립선 비대증 증상의 예방 및 치료에 효과적으로 작용할 수 있는 조성물에 관한 것이다.The present invention relates to a composition containing ginseng seed oil, which can effectively act in the prevention and treatment of symptoms of enlarged prostate gland in men.
본 발명에서 사용하는 인삼씨유는 그 가공 방법이 특별히 한정되지는 않으나, 예를 들어 도 1에 나타낸 가공 단계에 따라서 제조될 수 있다. 구체적으로는 다음과 같은 공정을 포함한다.The ginseng seed oil used in the present invention is not particularly limited in its processing method, but may be manufactured according to the processing steps shown in FIG. 1, for example. Specifically, the following process is included.
(a) 인삼열매로부터 인삼씨를 얻는 단계; 및(a) obtaining ginseng seeds from ginseng fruit; And
(b) 상기 단계에서 얻은 인삼씨를 착유하여 인삼씨유를 얻는 단계.(b) milking the ginseng seed obtained in the step to obtain ginseng seed oil.
상기 (a) 단계에서 인삼씨는 싹이 돋았거나 돋지 않은 것을 모두 포함하며, 생인삼씨일 수도 있고, 일광건조 또는 열풍건조를 통해 건조된 것일 수도 있다.The ginseng seed in step (a) includes both sprouted and non- sprouted, raw ginseng seeds, or may be dried through daylight drying or hot air drying.
본 발명에서 인삼씨를 착유하는 방법은 특별히 한정되지 않으며, 공지된 여러 가지 방법을 이용할 수 있다. The method of milking ginseng seed in the present invention is not particularly limited, and various known methods may be used.
본 발명에 따른 일 실시형태에서, 본 발명의 인삼씨유는 인삼씨를 착유기에 넣고 압착하여 유용성분을 추출하는, 인삼씨를 압착하는 압착법에 의해 얻어질 수 있다. 이 때, 식품용 착유기라면 제한없이 사용가능하며, 착유시간은 3~20분임이 바람직하며, 착유는 보통 상온에서 실시한다.In one embodiment according to the present invention, the ginseng seed oil of the present invention can be obtained by a compression method for compressing ginseng seed, which is put into the milking machine in the milking machine and compressed to extract useful components. At this time, if the milking machine for food can be used without limitation, the milking time is preferably 3 to 20 minutes, milking is usually carried out at room temperature.
본 발명에 따른 다른 실시형태에서, 인삼씨유는 초임계 추출법(Supercritical Water Extraction)으로 추출될 수 있다. 초임계 추출은 임계점을 넘은 상태의 초임계 유체를 이용하는 것으로서 사용하는 초임계 유체의 종류가 특별히 한정되는 것은 아니지만, 펜탄, 이산화탄소 등이 사용될 수 있으며, 특히 이산화탄소가 사용될 수 있다. 또한 사용하는 용매의 종류가 특별히 한정되는 것은 아니지만, 특히 본 발명에서는 용매로서 주정 또는 정제수를 사용할 수 있다.In another embodiment according to the present invention, ginseng seed oil may be extracted by Supercritical Water Extraction. Supercritical extraction is to use a supercritical fluid in a state beyond the critical point, but the type of supercritical fluid to be used is not particularly limited, pentane, carbon dioxide and the like can be used, in particular carbon dioxide may be used. Moreover, although the kind of solvent to be used is not specifically limited, Alcohol or purified water can be used especially as a solvent in this invention.
본 발명에 따른 다른 실시형태에서, 인삼씨유는 아임계 추출법(Subcritical Water Extraction)으로 추출될 수 있다. 아임계 추출은 용매가 임계점을 넘지 못한 상태에서 추출용매로 사용하는 것으로, 용매를 무엇으로 선택하는가에 따라서 초임계 추출과 같은 성능을 낼 수 있으며, 사용하는 용매의 종류가 특별히 한정되는 것은 아니지만, 특히 본 발명에서는 용매로서 주정 또는 정제수를 사용할 수 있다.In another embodiment according to the present invention, ginseng seed oil may be extracted by subcritical water extraction. Subcritical extraction is used as an extraction solvent when the solvent does not exceed the critical point, and depending on what solvent is selected, it can have the same performance as supercritical extraction, and the type of solvent used is not particularly limited. In particular, in the present invention, alcohol or purified water may be used as the solvent.
본 발명에 따른 다른 실시형태에서, 인삼씨유는 마이크로웨이브 추출법으로 추출될 수 있다. 마이크로웨이브 추출법은 용매를 줄이고 에너지를 최대한 절약하면서 단시간 내에 목적하는 성분을 추출할 수 있는 방법으로서, 사용하는 용매의 종류가 특별히 한정되는 것은 아니지만, 특히 본 발명에서는 용매로서 주정 또는 정제수를 사용할 수 있다.In another embodiment according to the present invention, ginseng seed oil may be extracted by microwave extraction. The microwave extraction method is a method that can extract the desired components in a short time while reducing the solvent and saving energy as much as possible, the type of the solvent used is not particularly limited, in particular in the present invention can be used as a solvent or purified water .
본 발명에 따른 다른 실시형태에서, 인삼씨유는 초음파 추출법으로 추출될 수 있다. 초음파 추출법은 추출물의 변성이나 손실없이 단시간 내에 효율적으로 유용성분을 추출할 수 있는 방법으로서, 사용하는 용매의 종류가 특별히 한정되는 것은 아니지만, 특히 본 발명에서는 용매로서 주정 또는 정제수를 사용할 수 있다.In another embodiment according to the present invention, ginseng seed oil may be extracted by ultrasonic extraction. Ultrasonic extraction is a method of extracting useful components efficiently within a short time without denaturation or loss of the extract, although the type of solvent to be used is not particularly limited, in particular in the present invention, alcohol or purified water can be used as the solvent.
본 발명의 조성물은 조성물의 형태에 따라 인삼씨유를 조성물 총 중량에 대하여 0.01~100중량%의 양으로 함유할 수 있다.The composition of the present invention may contain ginseng seed oil in an amount of 0.01 to 100% by weight based on the total weight of the composition, depending on the form of the composition.
또한, 본 발명의 조물은 정제, 환제, 단제, 캡슐제, 과립제, 산제, 연고제, 드링크제 또는 주사제 등의 형태로 약학 조성물 또는 식품 조성물로서 제형화할 수 있다.The preparations of the present invention may also be formulated as pharmaceutical or food compositions in the form of tablets, pills, tablets, capsules, granules, powders, ointments, drinks or injections.
본 발명은 통상적인 방법에 따라 인삼씨유를 추출물을 함유하는 약학 조성물을 제공한다. 약학 제형의 제조에 있어서, 활성 성분을 담체와 함께 혼합 또는 희석하거나, 용기 형태의 담체 내에 봉입시키는 것이 바람직하다. 담체가 희석제로 사용되는 경우에는 활성 성분에 대한 담체, 부형제 또는 매질(medium)로 작용하는 고형, 반고형 또는 액상의 물질일 수 있다. 따라서, 제형은 정제, 환제, 분제, 사쉐, 엘릭시르, 현탁제, 유제, 용액제, 시럽제, 에어로졸, 연질 또는 경질 젤라틴 캅셀제, 멸균 주사제, 멸균 분제 등의 형태일 수 있다.The present invention provides a pharmaceutical composition containing the extract of ginseng seed oil according to a conventional method. In the preparation of pharmaceutical formulations, it is preferred to mix or dilute the active ingredient with the carrier or to enclose it in a carrier in the form of a container. When the carrier is used as a diluent, it may be a solid, semisolid or liquid substance which acts as a carrier, excipient or medium for the active ingredient. Thus, the formulation may be in the form of tablets, pills, powders, sachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, soft or hard gelatin capsules, sterile injectables, sterile powders and the like.
적합한 담체, 부형제 및 희석제의 예로는, 락토로스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제형은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 포함할 수 있다. 본 발명의 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있다.Examples of suitable carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propyl Hydroxybenzoate, talc, magnesium stearate and mineral oil. The formulation may further comprise fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like. Compositions of the present invention may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
본 발명의 약학 조성물은 경구, 경피, 피하, 정맥, 복강, 근육, 국소도포, 첩포 및 이온토포레시스(iontophoresis)를 포함한 여러 경로를 통해 투여될 수 있고, 이 중에서 국소 적용 및 경구투여가 바람직하다.The pharmaceutical composition of the present invention may be administered through several routes including oral, transdermal, subcutaneous, intravenous, abdominal, muscle, topical application, patch and iontophoresis, of which topical application and oral administration are preferred. Do.
사람의 경우, 활성 화합물의 통상적인 1일 투여량은 1 내지 100mg/kg체중, 바람직하게는 5 내지 70mg/kg체중의 범위일 수 있고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성 성분의 실제 투여량은 치료할 질환, 투여 경로, 환자의 연령, 성별 및 체중, 및 질환의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.In humans, a typical daily dosage of the active compound may range from 1 to 100 mg / kg body weight, preferably 5 to 70 mg / kg body weight, and may be administered once or in several doses. However, it should be understood that the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease, and therefore the dosage may be determined in any way. Nor does it limit the scope of the present invention.
또한, 본 발명은 통상적인 방법에 따라 인삼 열매 추출물을 함유하는 식품 조성물을 제공한다.The present invention also provides a food composition containing the ginseng fruit extract according to a conventional method.
본 발명의 식품 조성물은 액상 또는 고체 상태의 제형을 갖는데 제형이 특별히 한정되지 않으며, 예를 들어, 정제, 과립제, 드링크제, 캬라멜, 다이어 트바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The food composition of the present invention has a formulation in a liquid or solid state, and the formulation is not particularly limited, and may be, for example, formulated into tablets, granules, drinks, caramels, diet bars, and the like. In addition to the active ingredient, the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
이하, 본 발명을 하기의 실시예 및 시험예를 통하여 설명한다. 실시예 및 시험예는 본 발명을 보다 상세히 설명하기 위한 것으로 본 발명의 범위가 하기의 실시예의 범위로 제한되는 것은 아니다.Hereinafter, the present invention will be described through the following examples and test examples. Examples and test examples are intended to explain the present invention in more detail, but the scope of the present invention is not limited to the scope of the following examples.
또한, 이 기술분야의 통상의 지식을 가진 자이면 누구나 이 발명의 기술 사상의 범주를 이탈하지 않고 첨부한 특허청구범위 내에서 다양한 변형 및 모방이 가능함은 명백한 사실이다.In addition, it is obvious that any person skilled in the art can make various modifications and imitations within the scope of the appended claims without departing from the scope of the technical idea of the present invention.
[실시예 1] 인삼씨유 제조Example 1 Preparation of Ginseng Seed Oil
인삼씨 전처리Ginseng Seed Pretreatment
생(生)인삼 열매를 수확하여 종자를 분리하여 인삼씨를 수득하였다.Raw ginseng fruit was harvested and seeds were separated to obtain ginseng seed.
인삼씨유의Ginseng oil 제조 Produce
식품용 착유기(DS-1500, 다산식품산업기계, 한국)를 상온에서 5분 동안 사용하여 상기와 같이 수득한 인삼씨로부터 인삼씨유를 얻었다(수율 0.5~2%).Ginseng seed oil was obtained from the ginseng seed obtained as above by using a food milking machine (DS-1500, Dasan Food Industry Machinery, Korea) at room temperature for 5 minutes (yield 0.5 ~ 2%).
이와 같이 얻은 인삼씨유를 하기 시험예에서 사용하였다.The ginseng seed oil thus obtained was used in the following test example.
[시험예 1] [Test Example 1]
<인삼씨유의 지방산 및 지질류 분석결과><Analysis Result of Fatty Acids and Lipids in Ginseng Seed Oil>
실시예 1에서 제조한 인삼씨유의 지방산 및 지질류 분석결과는 아래와 같다.Fatty acid and lipid analysis results of ginseng seed oil prepared in Example 1 are as follows.
성분ingredient 함량content
로르산(mg/100g)Loric Acid (mg / 100g) 2.52.5
식물스테롤(mg/100g)Phytosterols (mg / 100g) 7.387.38
식물스테롤에스테르(mg/100g)Phytosterol ester (mg / 100g) 10.510.5
공액리놀레산(mg/100g)Conjugated linoleic acid (mg / 100g) 1.41.4
Trans-9, trans-11 공액리놀레산 (mg/100g)Trans-9, trans-11 conjugated linoleic acid (mg / 100g) 1.041.04
옥타코사놀(mg/100g)Octacosanol (mg / 100g) 0.0050.005
인지질(mg/100g)Phospholipids (mg / 100g) 20.2120.21
감마리놀렌산(mg/100g)Gamma-linolenic acid (mg / 100g) 1.361.36
상기 표 1의 결과와 같이 본 발명에 따른 인삼씨유는 지방산 및 지질류가 검출되었다.As shown in Table 1, ginseng seed oil according to the present invention was detected fatty acids and lipids.
[시험예 2] 전립선 비대증 관련 삶의 질 평가 설문(BPH QoL-K1)Test Example 2 Quality of Life Assessment Questionnaire Related to Prostatic Hyperplasia (BPH QoL-K1)
전립선 비대증 관련 삶의 질을 평가하기 위해, 한국에서는 아래의 항목에 대하여 설문을 실시하고 있다(전립선비대증 관련 삶의 질에 대한 설문개발: 신뢰도 및 타탕성 검증, 대한비뇨기과학회지 41권 1호 2000년, 35-46).In order to assess the quality of life related to prostate hyperplasia, Korea is conducting a questionnaire on the following items (Development of a questionnaire on the quality of life related to prostate hypertrophy: Reliability and validity test, Journal of the Korean Journal of Urology, 41, 1 , 35-46).
(1) 평소 소변이 자주 마려워 불편하다.(1) I often feel uncomfortable urine often.
(2) 밤에 자다가 자주 일어나서 소변을 봐야 하기 때문에 불편하다. (2) I am uncomfortable because I have to get up and urinate frequently at night.
(3) 소변을 보고 난 후에도 소변이 떨어져 속옷을 적시는 것이 불편하다.(3) It is inconvenient to wet your underwear even after you urinate.
(4) 마음이 급한데 소변이 빨리 나오지 않아서 불편하다. (4) I am in a hurry, but urine does not come out quickly is uncomfortable.
(5) 소변을 봐도 시원하지 않아 불편하다. (5) It is uncomfortable because it is not cool even when urinating.
(6) 소변을 참기가 어려워 불편하다. (6) It is uncomfortable because it is difficult to hold urine.
(7) 소변 줄기가 가늘어 불편하다. (7) The urine stem is thin and uncomfortable.
(8) 몸이 피곤할 때는 소변이 잘 안나와서 불편하다. (8) When the body is tired, urine does not come out well is uncomfortable.
(9) 생식기 부위가 묵직하고 뻐근한 느낌 때문에 불편하다. (9) The genital area is uncomfortable because of heavy and stiff feeling.
(10) 소변을 보고 난 후에도 아랫배가 무겁고 찌릿한 느낌 때문에 불편하다.(10) I feel uncomfortable because my belly feels heavy and tingly after urinating.
(11) 소변이 자주 마려울까 봐 음료수를 안 마시게 된다.(11) I don't drink because I'm afraid of frequent urination.
(12) 소변을 자주 보기 때문에 일하는데 지장을 받는다.(12) Because of frequent urination, it is difficult to work.
(13) 장거리 여행을 할 때 소변이 자주 마려워서 불편하다.(13) I am uncomfortable with frequent urination when I travel long distances.
(14) 술자리에서 남보다 자주 화장실에 가는 것이 불편하다.(14) It is inconvenient to go to the toilet more often than others in drinking.
(15) 등산을 가거나 야외 활동을 하기가 불편하다.(15) It is inconvenient to go hiking or to do outdoor activities.
(16) 소변을 자주 보기 때문에 외출하는 것이 신경이 쓰인다. (16) I urinate often, so I'm worried about going out.
(17) 오랜 시간 차를 타는 것이 불안하고 긴장이 된다.(17) Driving for a long time is anxious and nervous.
(18) 깊은 잠을 들기가 어렵다.(18) It is difficult to get a deep sleep.
(19) 매사에 적극적이지 못하고 의욕이 없다.(19) He is not active and motivated in everything.
(20) 한가지 일에 집중하기가 어렵다.(20) It's hard to concentrate on one thing.
(21) 특별한 이유없이 자주 신경질이 나는 편이다. (21) I often get nervous for no reason.
(22) 공연히 매사에 걱정을 하거나 근심이 많다.(22) There is a lot of worry or worry about everything.
(23) 소변이 자주 마려워 교회, 절에 가는 등의 종교활동을 하는 것이 어렵다.(23) It is difficult to do religious activities, such as going to church or temples because of frequent urination.
(24) 모임 등에 참석해 다른 사람들과 어울리는 것이 신경이 쓰인다. (24) I am worried about attending meetings and hanging out with others.
(25) 노후에 건강한 삶을 살 수 있을지 자신이 없다.(25) I am not sure whether I can live a healthy life in old age.
(26) 자신의 건강 상태에 대해서 걱정을 많이 한다.(26) I worry a lot about my health.
(27) 나이들면 상태가 더 악화되고 계속 치료를 받아야 할지 걱정이 된다.(27) As you age, your condition worsens and you are worried about continuing treatment.
(28) 자신의 병이 악성으로 진행될까봐 걱정이 된다.(28) I am worried that my illness will be malignant.
(29) 앞으로 증세가 더 악화되면 소변을 아예 못보게 될까봐 걱정이 된다. (29) I'm worried that I will not be able to urinate if the symptoms worsen in the future.
(30) 성적욕구가 전에 비해 감소했다.(30) Sexual desire has decreased compared to before.
(31) 발기가 잘 안된다.(31) Erection is not good.
(32) 발기가 되더라도 금방 시들해지거나 정액이 시원하게 배출되지 않는다.(32) Even if an erection occurs, it does not quickly wither or discharge semen.
(33) 성적으로 뭔가 부족하고 자신감이 없다.(33) There is something lacking in sexuality and lack of confidence.
(34) 자주 피곤함을 느낀다.(34) I often feel tired.
(35) 몸에 기력이 떨어져서 마음대로 활동하기가 힘들다.(35) It is difficult to work freely because of lack of energy in the body.
상기 35가지 항목을 “0: 전혀 불편하지 않다. 1: 거의 불편하지 않다. 2: 견딜 만 하다. 3: 불편하다. 4: 매우 불편하다. 5: 견딜 수 없다.”에 해당하는 점수로 체크를 하여 총점을 합하여 전립선 비대증 관련 삶의 질을 평가한다.The above 35 items are “0: not inconvenient at all. 1: It is almost uncomfortable. 2: endurable 3: It's uncomfortable. 4: Very uncomfortable. 5: unbearable ”and add up your overall score to assess your quality of life related to prostatic hyperplasia.
평소 소변에 불편함을 느끼는 40대 이상 남성 60명을 대상으로 처음 설문을 진단설문을 작성하게 하였고, 그 후 상기 60명을 20명씩 3개 군으로 나누었다. 이 중 하나의 군에 대해서는 상기 실시예 1의 인삼씨유를 1ml 씩 분획이 가능한 스포이드 용기에 담아 28번 우유에 함유시켜 섭취하게 하였다. 즉, 표준화시킨 인삼씨유를 1일 1회 28ml씩 섭취하게 하였다(인삼씨유 섭취군). 또한, 다른 하나의 군에 대해서는 비교를 위하여 로르산을 섭취하게 하였다. 구체적으로는 콩기름 1ml에 로르산 2.5mg을 녹여서 로르산이 용해된 콩기름을 1일 1회 28ml(즉, 총 로르산의 함량 70mg, 인삼씨유 28ml에 함유된 로르산의 양과 동일)씩 섭취하게 하였다(로르산 섭취군). 또한 다른 하나의 군에 대해서는 다른 유효성분이 포함되지 않은 콩기름을 1일 1회 28ml씩 섭취하게 하였다(미섭취군). 이렇게 약 4주간 섭취하게 한 후 다시 진단설문을 작성하게 하여 인삼씨유, 로르산 또는 콩기름의 섭취전과 후를 비교하였다.The first questionnaire was made for 60 males over 40 with discomfort in urine. The 60 patients were divided into three groups of 20 people. For one of these groups, the ginseng seed oil of Example 1 was contained in a dropper container capable of fractionation of 1 ml and contained in 28 milk. That is, the standardized ginseng seed oil was ingested 28ml once a day (ginseng seed oil intake group). In addition, the other group was given loric acid for comparison. Specifically, 2.5 mg of loric acid was dissolved in 1 ml of soybean oil, so that 28 ml of soybean oil in which lauric acid was dissolved (ie, 70 mg of total loric acid and the same amount of lauric acid in 28 ml of ginseng seed oil) was consumed. (Loric acid intake group). In addition, the other one group was ingested 28ml of soybean oil once a day that does not contain other active ingredients (not ingested group). After ingestion for about 4 weeks, the diagnostic questionnaire was made again and compared with before and after ingestion of ginseng seed oil, loric acid or soybean oil.
결과는 진단설문 평가 점수의 변화로 하기 표 2에 나타내었다(N=60).The results are shown in Table 2 as a change in the diagnostic questionnaire score (N = 60).
섭취 전Before intake 섭취 후After ingestion 그 변화의 정도The degree of change
미섭취군(명)Intake group (person) 2020 미섭취군(명)Intake group (person) 2020 00
총점(점)Total score 145145 총점(점)Total score 144144 -1-One
로르산 섭취군 (명)Loric Intake Group (Person) 2020 미섭취군(명)Intake group (person) 2020 00
총점(점)Total score 140140 총점(점)Total score 110110 -30-30
인삼씨유섭취군(명)Ginseng seed oil intake group (persons) 2020 인삼씨유섭취군(명)Ginseng seed oil intake group (persons) 2020 00
총점(점)Total score 142142 총점(점)Total score 102102 -40-40
상기 표 2에 나타낸 바와 같이, 인삼씨유를 섭취한 피험자들의 진단설문 평가 점수가 더 낮았으며, 이는 전립선 평활근 이완에 의해 전립선 비대증상을 완화시켜 전립선 건강에 좋은 것으로 알려져 있는 로르산을 섭취한 경우와 비교하여, 개선 정도가 현저하게 크다는 것을 알 수 있다. 따라서 이를 통해 인삼씨유의 섭취로 전립선 비대증 증상이 개선되는 것을 확인할 수 있다. As shown in Table 2, the score of the diagnostic questionnaire was lower for the subjects who consumed ginseng seed oil, and the ingestion of luteic acid, which is known to be good for prostate health by relieving the enlargement of the prostate gland by prostate smooth muscle relaxation, was taken. Compared with, it can be seen that the degree of improvement is remarkably large. Therefore, it can be seen that the intake of ginseng seed oil improves the symptoms of enlarged prostate.
본 발명의 일 실시예에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Examples of the formulation of the composition according to an embodiment of the present invention will be described below, but it is also applicable to various other formulations, which are intended to explain in detail only and not intended to limit the present invention.
[제형예 1] 인삼씨유 100% 엑기스Formulation Example 1 Ginseng Seed Oil 100% Extract
실시예 1의 인삼씨유 제조 시 고형분의 함량이 20% 이상이 되도록 농축하여, 저온에서 숙성한 후 액상형태의 100% 엑기스 제품을 제조하였다.The ginseng seed oil of Example 1 was concentrated so that the content of solid content was 20% or more, and matured at low temperature to prepare 100% extract product in liquid form.
[제형예 2] 연질캅셀제Formulation Example 2 Soft Capsule
실시예 1의 인삼씨유 110mg, 팜유 0.8mg, 식물성 경화유 0.48mg, 황납 2.4mg 및 레시틴 3.6mg을 혼합하고, 통상의 방법에 따라 충진하여 연질 캅셀을 제조하였다.110 mg of ginseng seed oil, 0.8 mg of palm oil, 0.48 mg of vegetable hardened oil, 2.4 mg of lead, 2.4 mg of lecithin and 3.6 mg of lecithin were mixed and filled according to a conventional method to prepare a soft capsule.
[제형예 3] 정제Formulation Example 3 Tablet
실시예 1의 인삼씨유 160mg, 포도당 200㎎ 및 덱스트린 196㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 7mg을 첨가하여 타정기로 타정하여 정제를 제조하였다.160 mg of ginseng seed oil, 200 mg of glucose, and 196 mg of dextrin were mixed and granulated using a fluidized bed dryer, and then, 7 mg of sugar ester was added thereto, and tableted with a tablet press to prepare a tablet.
[제형예 4] 환의 제조Formulation Example 4 Preparation of Ring
실시예 1의 인삼씨유 0.9g, 당 0.3g, 전분 1.91g 및 글리세린 0.56g을 혼합하고, 제환기를 사용하여 환을 제조하였다.0.9 g of ginseng seed oil of Example 1, 0.3 g of sugar, 1.91 g of starch, and 0.56 g of glycerin were mixed, and a ring was prepared using a dehydrator.
[제조예 5] 과립제Production Example 5 Granules
실시예 1의 인삼씨유 160mg, 포도당 200㎎ 및 덱스트린 196㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후, 포에 충진하여 과립제를 제조하였다.160 mg of ginseng seed oil, 200 mg of glucose, and 196 mg of dextrin were mixed and granulated using a fluidized bed dryer, followed by filling into a fabric to prepare granules.
[제조예 6] 드링크제[Manufacture example 6] Drink system
실시예 1의 인삼씨유 110mg, 포도당 10g 및 구연산 2g을 혼합한 후 정제수 188g을 가하여 각 병에 200㎖씩 충진되도록 하였다. 병에 충진한 다음 90℃에서 2∼3시간 살균하여 음료를 제조하였다.110 mg of ginseng seed oil, 10 g of glucose, and 2 g of citric acid were mixed, and then 188 g of purified water was added thereto, and 200 ml of each bottle was filled. After filling the bottle and sterilized 2-3 hours at 90 ℃ to prepare a beverage.

Claims (4)

  1. 인삼씨유를 유효성분으로 함유하는 전립선 비대증 예방 및 치료용 조성물.Prostate hypertrophy prevention and treatment composition containing ginseng seed oil as an active ingredient.
  2. 제1항에 있어서, 상기 조성물은 인삼씨유를 조성물 총 중량에 대하여 0.01∼100중량%의 양으로 함유함을 특징으로 하는 전립선 비대증 예방 및 치료용 조성물.The composition for preventing and treating prostatic hyperplasia according to claim 1, wherein the composition contains ginseng seed oil in an amount of 0.01 to 100% by weight based on the total weight of the composition.
  3. 제1항 또는 제2항에 있어서, 상기 조성물은 약학 조성물 또는 식품 조성물로 제형화됨을 특징으로 하는 전립선 비대증 예방 및 치료용 조성물.The composition for preventing and treating prostatic hyperplasia according to claim 1 or 2, wherein the composition is formulated as a pharmaceutical composition or a food composition.
  4. 인삼씨유를 함유하는 조성물에 있어서, 인삼씨유의 전립선 비대증 예방 및 치료용으로서의 용도.Use of ginseng seed oil as a composition for preventing and treating prostatic hyperplasia in ginseng seed oil.
PCT/KR2015/011246 2014-10-31 2015-10-23 Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy WO2016068547A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2017523344A JP6615200B2 (en) 2014-10-31 2015-10-23 Composition for prevention and treatment of benign prostatic hyperplasia containing carrot seed oil, and formulation obtained by formulating the composition
CN201580059489.2A CN106999524B (en) 2014-10-31 2015-10-23 Composition containing ginseng seed oil for preventing and treating prostatic hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2014-0149716 2014-10-31
KR1020140149716A KR102273967B1 (en) 2014-10-31 2014-10-31 Composition for preventing and treating prostatic hypertrophy containing ginseng seed oil

Publications (1)

Publication Number Publication Date
WO2016068547A1 true WO2016068547A1 (en) 2016-05-06

Family

ID=55857807

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/011246 WO2016068547A1 (en) 2014-10-31 2015-10-23 Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy

Country Status (4)

Country Link
JP (1) JP6615200B2 (en)
KR (1) KR102273967B1 (en)
CN (1) CN106999524B (en)
WO (1) WO2016068547A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210298339A1 (en) * 2020-03-31 2021-09-30 Amorepacific Corporation Composition comprising ginseng seed oil

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082696A1 (en) * 2003-03-20 2004-09-30 Laboratorios Dalmer S.A. Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits
KR20120124608A (en) * 2011-05-04 2012-11-14 이현기 Health-aid food used the ginseng seed oil by main raw material
KR20130029866A (en) * 2011-09-16 2013-03-26 초임계연구소 주식회사 Process for preparing ginseng seed oil of high oxidative stability and low color with supercritical fluid
KR20140055348A (en) * 2012-10-31 2014-05-09 세명대학교 산학협력단 Extract of ginseng seed, composition or oil having the same, and preparing method thereof
KR101452320B1 (en) * 2014-03-11 2014-10-22 주식회사 벤스랩 FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101134054A (en) * 2006-08-30 2008-03-05 北京欧纳尔生物工程技术有限公司 Pharmaceutical composition for improving urination disorders caused by BPH and method for making the same
JP5628797B2 (en) * 2008-06-13 2014-11-19 アモーレパシフィック コーポレイションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ Skin external preparation composition containing ginseng flower or ginseng seed extract

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004082696A1 (en) * 2003-03-20 2004-09-30 Laboratorios Dalmer S.A. Pharmaceutical composition and method for the treatment and prevention of prostatic hyperplasia and prostatitis using roystonea regia (royal palm) fruits
KR20120124608A (en) * 2011-05-04 2012-11-14 이현기 Health-aid food used the ginseng seed oil by main raw material
KR20130029866A (en) * 2011-09-16 2013-03-26 초임계연구소 주식회사 Process for preparing ginseng seed oil of high oxidative stability and low color with supercritical fluid
KR20140055348A (en) * 2012-10-31 2014-05-09 세명대학교 산학협력단 Extract of ginseng seed, composition or oil having the same, and preparing method thereof
KR101452320B1 (en) * 2014-03-11 2014-10-22 주식회사 벤스랩 FERMENTED CAMELLIA JAPONICA SEED OIL INHIBITING 5-α REDUCTASE FOR IMPROVEMENT OF BENIGN PROSTATIC HYPERPLASIA AND ALOPECIA

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210298339A1 (en) * 2020-03-31 2021-09-30 Amorepacific Corporation Composition comprising ginseng seed oil
US11717012B2 (en) * 2020-03-31 2023-08-08 Amorepacific Corporation Composition comprising ginseng seed oil

Also Published As

Publication number Publication date
JP6615200B2 (en) 2019-12-04
KR20160052001A (en) 2016-05-12
CN106999524A (en) 2017-08-01
KR102273967B1 (en) 2021-07-08
CN106999524B (en) 2021-01-15
JP2018500285A (en) 2018-01-11

Similar Documents

Publication Publication Date Title
WO2015002391A1 (en) Composition having a function for alleviating premenstrual syndrome and menstrual pain
WO2018164325A1 (en) Composition for remedying female climacteric syndrome symptoms
WO2021201532A1 (en) Composition for preventing, alleviating or treating female menopausal syndrome, containing rosa rugosa extract as active ingredient
Hamburger et al. Bryophyllum pinnatum–reverse engineering of an anthroposophic herbal medicine
WO2013100340A1 (en) Composition comprising dendropanax morbiferus extract for improving male sexual function
KR101969757B1 (en) Composition comprising fermented extracts for acne treatment
CN102068440A (en) Drug composition for treating cardio-cerebrovascular diseases and preparation method
WO2014200234A1 (en) Composition containing composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms
KR20200136207A (en) Composition for anti-allergy comprising extract of lithospermum erythrorhizon
WO2016186349A2 (en) Composition, containing quisaqualis indica extract, for preventing or treating prostatic hyperplasia
JP2017197519A (en) Composition for ameliorating climacteric symptoms or osteoporosis
WO2020231031A2 (en) Composition comprising lactobacillus acidophilus for preventing, alleviating, or treating arthromyalgia, headaches, or vaginal dryness in climacteric women
WO2016068547A1 (en) Composition containing ginseng seed oil for prevention and treatment of prostatic hypertrophy
KR100522579B1 (en) Pharmaceutical composition comprising the extracts of scutellaria root and schizandra fruit mixture thereof having an effect of restraint stress
KR20210130595A (en) Composition for sensitive skin comprising Bidens plant extracts
WO2016093613A2 (en) Composition for preventing or treating abnormal weight loss, containing citrus unshiu peel extract
WO2023038258A1 (en) Novel lactobacillus gasseri lm1065 strain derived from breast milk, and composition for alleviating premenstrual syndrome comprising said strain or culture product thereof
JP2018506524A (en) Composition for prevention, amelioration or treatment of burnout syndrome
KR101119410B1 (en) Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases
KR102465484B1 (en) Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing heat-killed enteroccocus faecalis as an active ingredient
KR101131719B1 (en) Pulsatilla koreana extracts compositions for treating or preventing inflammatory diseases
WO2011019153A2 (en) Composition for preventing or treating arthritis, containing an extract of an herbal medicine mixture of schisandra chinensis baillon, scutellaria baicalensis and kalopanax pictus nakai as an active ingredient
FR2813790A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING SOY ISOFLAVONE EXTRACTS AND PROBIOTIC MICROORGANISMS
KR20150006224A (en) A composition comprising an extract of combined crude drugs for treating and preventing abnormal metabolic diseases
KR20170133820A (en) Composition for relieving menopausal symptom or osteoporosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15853873

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017523344

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15853873

Country of ref document: EP

Kind code of ref document: A1